{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T03:40:05Z","timestamp":1792381205955,"version":"4.4.0"},"reference-count":46,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100014471","name":"Mundipharma Research Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>Take\u2010home naloxone (THN) programmes have been introduced in many European countries to provide non\u2010medically trained people who are likely to witness an opioid overdose, including people who use opioids, with a naloxone kit and training. This study used data obtained from people supplied with THN and systematically followed up for 6 months to determine the proportion witnessing an overdose, administering naloxone and successfully reversing opioid overdose in real\u2010world settings. The study aimed to compare reports of witnessed opioid overdose between participants in treatment and not in treatment at the time of recruitment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A multi\u2010country, observational prospective cohort study. Participants supplied with THN were asked to report any witnessed overdose events and participate in a systematic follow\u2010up over a 6\u2010month period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Participants were recruited from THN programmes at 22 drug treatment and harm reduction services in England, Wales, Scotland and Sweden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A total of 1025 people who used opioids and who were supplied with THN were recruited between June 2021 and November 2023, of whom 594 (58%) were successfully followed at 6\u2009months. The participants were predominantly men (75%) and white (80%), with a mean age of 45.5\u00a0years (standard deviation 10).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurement<\/jats:title>\n                    <jats:p>Main outcomes: whether or not THN was administered at a witnessed overdose and overdose outcome where THN administered. Accurate recognition of opioid overdose, availability of naloxone and appropriate responses (including administering naloxone) to an opioid overdose were captured. Outcomes were compared between participants in treatment and not in treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>\n                      Of the 594 followed over 6 months, 160 (27%) witnessed at least one overdose. The likelihood of witnessing an overdose was higher among participants not in treatment than participants in treatment [56% vs.\u00a023%; odds ratio\u2009=\u20094.4; 95% confidence interval (CI) = 2.69\u20137.21;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001]. THN was administered at most witnessed overdose events (83%; 95% CI = 74\u201385). Seven deaths were reported (4.4%; 95% CI = 0.02\u20138.8) by participants to be due to an overdose. For five deaths, naloxone was administered but was believed by participants to have been administered after death. Ninety\u2010five percent (152) of participants were able to recognise one or more critical signs of overdose and respond appropriately. When naloxone was available, it was administered in almost all (90%; 142) emergency situations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the United Kingdom and Sweden, people who use opioids appear to be likely to witness and recognise an opioid overdose, be the only person carrying naloxone at the overdose and be both willing and able to safely and effectively administer naloxone in a timely response.<\/jats:p>\n                    <jats:p>\n                      Clinical trial registration details (if applicable):\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      Identifier: NCT05072249. Date of Registration: 8.10.2021.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.70526","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T04:19:14Z","timestamp":1783916354000},"page":"3025-3039","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overdose reversal through peer intervention: Findings from the naloxone prospective outcome research study (NalPORS) on the effectiveness of overdose response by people who use opioids in the United Kingdom and Sweden"],"prefix":"10.1111","volume":"121","author":[{"given":"Nicola","family":"Metrebian","sequence":"first","affiliation":[{"name":"National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Dascal","sequence":"additional","affiliation":[{"name":"National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Mackie","sequence":"additional","affiliation":[{"name":"National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Tinch\u2010Taylor","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0318-8865","authenticated-orcid":false,"given":"Ben","family":"Carter","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1502-5983","authenticated-orcid":false,"given":"Joanne","family":"Neale","sequence":"additional","affiliation":[{"name":"National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Gonzalez","family":"Utrilla","sequence":"additional","affiliation":[{"name":"National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Day","sequence":"additional","affiliation":[{"name":"Birmingham and Solihull Mental Health NHS Foundation Trust  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joar","family":"Guterstam","sequence":"additional","affiliation":[{"name":"Stockholm Centre for Dependency Disorders, Stockholm, Sweden, Department of Global Public Health Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Horsburgh","sequence":"additional","affiliation":[{"name":"Scottish Drugs Forum  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"K\u00e5berg","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services, Stockholm County Council  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Kelleher","sequence":"additional","affiliation":[{"name":"South London and Maudsley NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Mayet","sequence":"additional","affiliation":[{"name":"Humber Teaching NHS Foundation Trust  Hull UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7671-104X","authenticated-orcid":false,"given":"Josie","family":"Smith","sequence":"additional","affiliation":[{"name":"Public Health Wales  Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Eide","sequence":"additional","affiliation":[{"name":"Norwegian Centre for Addiction Research University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Holm\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services, Stockholm County Council  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"McDonald","sequence":"additional","affiliation":[{"name":"National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Parkin","sequence":"additional","affiliation":[{"name":"National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Thiesen","sequence":"additional","affiliation":[{"name":"Sundheds Team  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5413-2725","authenticated-orcid":false,"given":"John","family":"Strang","sequence":"additional","affiliation":[{"name":"National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King's College London  London UK"},{"name":"South London and Maudsley NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"United Nations Office on Drugs and Crime.Opioid Overdose: Preventing and Reducing Opioid Overdose Mortality.2013.http:\/\/www.unodc.org\/docs\/treatment\/overdose.pdf"},{"key":"e_1_2_11_3_1","unstructured":"Australian Bureau of Statistics.Drug Induced Deaths in Australia: A changing story.2017.http:\/\/www.abs.gov.au\/ausstats\/abs@.nsf\/Lookup\/by%20Subject\/3303.0~2016~Main%20Features~Drug%20Induced%20Deaths%20in%20Australia~6"},{"key":"e_1_2_11_4_1","unstructured":"Office of National Statistics.Deaths related to drug poisoning in England and Wales: 2022 registrations.2022.https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsrelatedtodrugpoisoninginenglandandwales\/2022registrations"},{"key":"e_1_2_11_5_1","volume-title":"WHO model list of essential medicines","author":"WHO","year":"2013"},{"key":"e_1_2_11_6_1","unstructured":"European Union Drugs Agency.European Drug Report; Heroin and other opioids \u2013 the current situation in Europe (European Drug Report 2023).https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2023\/heroin-and-other-opioids_enAccessed 24.09.24"},{"key":"e_1_2_11_7_1","unstructured":"European Union Drugs Agency.European Drug Report 2024. Drug\u2010induced deaths \u2013 the current situation in Europe (European Drug Report 2024).https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2024\/drug-induced-deaths_en"},{"issue":"0","key":"e_1_2_11_8_1","first-page":"525","article-title":"Metabolism and pharmacokinetics of naloxone","volume":"8","author":"Weinstein SH","year":"1973","journal-title":"Adv Biochem Psychopharmacol"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01154-5"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.017.05.001"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02314.x"},{"key":"e_1_2_11_12_1","unstructured":"United States Food and Drug Administration.Naloxone for treatment of opioid overdose.2016.https:\/\/www.fda.gov\/downloads\/Advisofopioidoverdose.2016.https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee\/UCM522690.pdf"},{"key":"e_1_2_11_13_1","unstructured":"World Health Organisation.Community management of opioid overdose.2014.http:\/\/www.who.int\/substance_abuse\/publications\/management_opioid_overdose\/en\/"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2005.05.010"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.02.031"},{"key":"e_1_2_11_16_1","first-page":"631","article-title":"Opioid overdose prevention programs providing naloxone to laypersons \u2010 United States, 2014","volume":"64","author":"Wheeler E","year":"2015","journal-title":"Morb Mortal Wkly Rep"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2008.146647"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.759"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2191-1"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14033"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-023-00533-2"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13326"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12523"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.12.013"},{"key":"e_1_2_11_25_1","unstructured":"Thylstrup Harm Reduction Journal 2019 [to add]"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-16445-6"},{"issue":"1","key":"e_1_2_11_27_1","first-page":"92","article-title":"Naloxone distribution and possession following a large\u2010scale","volume":"114","author":"Madah\u2010Amiri D","year":"2019","journal-title":"Naloxone Programme Addict"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000521197"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.110815"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.10.008"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00474.x"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000034"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-022-00700-x"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-210391"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826080701801261"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14510"},{"key":"e_1_2_11_37_1","unstructured":"World Health Organization.UNODC\u2010WHO Stop\u2010Overdose\u2010Safely (SOS) project implementation in Kazakhstan Kyrgyzstan Tajikistan and Ukraine: summary report.2021."},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-025-01203-1"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1300\/J069v26n04_08"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1996.91341310.x"},{"key":"e_1_2_11_41_1","unstructured":"National Records of Scotland.Drug\u2010related deaths in Scotland in 2022. Published on 22 August2023."},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/09687637.2012.671860"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13265"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.103059"},{"key":"e_1_2_11_45_1","unstructured":"European Drug Report.Trends and Developments (European Drug Report 2020). European Union Drugs Agency.https:\/\/www.euda.europa.eu\/publications\/edr\/trends-developments\/2020_en"},{"key":"e_1_2_11_46_1","unstructured":"Public Health England.An evidence review of the outcomes that can be expected of drug misuse treatment in England.2017."},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232086"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.70526","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.70526","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.70526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T02:56:44Z","timestamp":1792378604000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.70526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1111\/add.70526"],"URL":"https:\/\/doi.org\/10.1111\/add.70526","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]},"assertion":[{"value":"2026-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}